Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
An investigation of overall survival (OS) among elderly patients with estrogen receptor (ER)–positive, node-positive breast cancer resulted in findings of greater OS, despite a greater disease burden and the presence of comorbidities, following adjuvant chemotherapy, says the study published in JAMA Oncology.
“Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer,” the authors noted. A principal reason for this is the frequent exclusion of this age group from clinical trials.
Their restrospective cohort study analyzed data on 2,445,870 patients included in the US National Cancer Database, with 1592 meeting inclusion criteria (≥70 years; Charlson/Deyo comorbidity score of 2 or 3; ER-positive, ERBB2 [formerly HER2 or HER2/neu]–negative disease; surgery for pathologic node-positive breast cancer between January 1, 2010, and December 31, 2014). Their mean (SD) age was 77.5 (5.5) years, and 96.9% were female.
Overall, 22% of the included patients received chemotherapy, with younger age (74 vs 78 years; P < .001), larger primary tumor size (pT3/T4 tumors: 20.6% vs 14.7%; P = .005), and higher pathological nodal burden (stage pN3 disease: 21.4% vs 6.5%; stage pN1 disease: 52.0% vs 75.4%; P < .001) associated with its receipt.
There was also a greater likelihood of endocrine therapy (88.3% vs 82.5%; P = .01) and radiation therapy (67.4% vs 43.5%; P < .001) among the chemotherapy cohort.
Results were encouraging for OS, in that a positive correlation was seen between receipt of chemotherapy and OS (HR, 0.67; 95% CI, 0.48-0.93; P = .02), after adjusting for potential confounding factors. However, a statistically significant difference in median OS was not seen prior between the chemotherapy and no-chemotherapy groups: 78.9 months (95% CI, 78.9 months–not reached) vs 62.7 months (95% CI, 56.2 months–not reached; P = .13).
The nonmatched cohort had a median follow-up of 43.1 (95% CI, 39.6-46.5) months, whereas that for the entire group was 59.5 (95% CI, 55.0-65.6) months.
Age, Charlson/Deyo comorbidity score, facility type and location, pathologic T and N stage, and receipt of adjuvant endocrine or radiation therapy were used to match patients receiving chemotherapy to those not receiving it. Data were analyzed from December 13, 2018, through April 28, 2020, and the primary outcome was the link between OS and adjuvant chemotherapy.
Additional analyses revealed a worse OS was more likely in the matched cohort under the following conditions:
“Despite attempts to adjust for selection bias, these findings suggest that physicians carefully selected patients likely to derive treatment benefit from adjuvant chemotherapy based on certain unmeasured variables,” the authors concluded. “A standardized, multidisciplinary approach to care may be associated with long-term treatment outcomes in this subset of the population.
Possible study limitations include coding inaccuracies and underreporting of comorbidities associated with the Charlson/Deyo comorbidity score, as well as the influence of unmeasured variables and lack of breast cancer-specific survival data in the National Cancer Database.
Reference
Tamirisa N, Lin H, Shen Y, et al. Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol. 2020;6(10):1548-1554. doi:10.1001/jamaoncol.2020.2388
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More